Table 1

RCAaanalysis of azole–resistant C. albicans isolates with known ERG11 mutationsb.

MIC (μg/ml)


Patient no.

Isolate

no.

Body site of

isolation

FLUa

VORa

Previously-characterized

amino acid substitution(s)

Erg11p

substitution(s) by RCA


1

C438

Oropharynx

128

2

Y257H, G464S

Y257H, G464S

C440

Oropharynx

>256

>16

A61V, Y257H, G307S, G464S

A61V, Y257H, G307S, G464S

2

C470

Oropharynx

32

0.25

S405F

S405F

3

C480

Oropharynx

128

8

G464S, K128T, R467I

G464S, K128T, R467I

4

C507

Oropharynx

64

8

G464S, H283R, Y132H

G464S, H283R, Y132H

5

C527

Oropharynx

256

4

G450E, Y132H

G450E, Y132H

6

C577

Oropharynx

128

0.5

G464S

G464S

7

C594

Oropharynx

128

16

S405F, Y132H

S405F, Y132H


a Abbreviations: RCA, rolling circle amplification; FLU, fluconazole; VOR, voriconazole.

b Chau et al. [15].

Wang et al. BMC Microbiology 2009 9:167   doi:10.1186/1471-2180-9-167

Open Data